Back to Search
Start Over
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
- Source :
- Molecular and Clinical Oncology
- Publication Year :
- 2017
-
Abstract
- The authors present a case report of collecting duct carcinoma (CDC) that responded to nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following the failure of systemic treatment with chemotherapy and targeted therapy. The patient underwent right radical nephrectomy and segmentectomy of the lung following chemotherapy. Fifteen months following the first surgery, segmentectomy and subsequent second-line chemotherapy were performed for recurrence in the lung. Targeted therapy with temsirolimus for recurrence of the lung and lymph node metastases was ultimately used for 30 months. However, the temsirolimus treatment failed to suppress the growth of metastatic lesions. Nivolumab resulted in complete response of the lung metastasis, and it stabilized the lymph node metastasis. PD-L1 was highly expressed in both primary tumor and the metastatic regions. Therapy with nivolumab is ongoing. These findings suggest that treatment with nivolumab may be considered for metastatic and treatment-failure CDC.
- Subjects :
- Oncology
PD-L1
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
non-clear renal cell carcinoma
Biology
Targeted therapy
03 medical and health sciences
Collecting duct carcinoma
0302 clinical medicine
Internal medicine
PD-1
medicine
030212 general & internal medicine
Lymph node
nivolumab
Chemotherapy
Cancer
Articles
medicine.disease
Primary tumor
Temsirolimus
medicine.anatomical_structure
030220 oncology & carcinogenesis
collecting duct carcinoma
Nivolumab
medicine.drug
Subjects
Details
- ISSN :
- 20499450
- Volume :
- 7
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Molecular and clinical oncology
- Accession number :
- edsair.doi.dedup.....36fd2fdc782806c9eafeffe504bd18f7